Dr Yves Fradet graduated from Laval University (Quebec, Canada) in 1981 and completed an oncology fellowship at the Memorial Sloan-Kettering Cancer Center, with Drs Willet Whitmore and Lloyd Old. In 1983 he founded, at the Laval University Cancer Research Center, a translational and clinical research laboratory  in urological cancers whose work are supported continuously for more than 30 years.

Dr Fradet still has a very active practice in uro-Oncology within the Urologic Oncology Section and the Urology Service at the CHU de Québec- Hôtel-Dieu de Québec where he has grouped a team of specialists among the most important in Canada including seven uro-oncologists, three of which are also holders of PhD.

He is a member of many national and international societies, including since 2001, the American Association of Genitourinary Surgeons in which he was invited to be part of the 75 members in America. More recently, he was appointed international honorary member of the Association of Academic European Urology, membership awarded to those who have had important influence on urology. Dr Fradet is often invited as a guest speaker at national and international meetings, as a visiting professor, and as a consultant to many organizations. He was the founding chairman of the Canadian Urologic Oncology Group from 1988 to 1995 and chairman of the Department of Surgery at Laval University from 2000 to 2008. He has authored over 330 publications and book chapters and more than 600 abstracts.

Hôpital de l'Enfant-Jésus
1401, 18e rue
G4.610
Québec, QC
Canada G1J 1Z4
+1 418-525-4444, extension 67694+1 418-691-3154
Yves.Fradet@crchudequebec...

Latest news

353 entries « ‹ 4 of 36 › »

Bilodeau JF, Gevariya N, Larose J, Robitaille K, Roy J, Oger C, Galano JM, Bergeron A, Durand T, Fradet Y, Julien P, Fradet V

Long chain omega-3 fatty acids and their oxidized metabolites are associated with reduced prostate tumor growth

Journal Article

Prostaglandins Leukot Essent Fatty Acids, 164 , 2021.

Abstract | Links:

Toren P, Brisson H, Simonyan D, Hovington H, Lacombe L, Bergeron A, Fradet Y

Androgen receptor and immune cell PD-L1 expression in bladder tumors predicts disease recurrence and survival

Journal Article

World J Urol, 39 (5), 2021.

Abstract | Links:

Lévesque E, Labriet A, Hovington H, Allain ÉP, Melo-Garcia L, Rouleau M, Brisson H, Turcotte V, Caron P, Villeneuve L, Leclercq M, Droit A, Audet-Walsh E, Simonyan D, Fradet Y, Lacombe L, Guillemette C

Alternative promoters control UGT2B17-dependent androgen catabolism in prostate cancer and its influence on progression

Journal Article

Br J Cancer, 122 (7), 2020.

Abstract | Links:

Al-Hogbani M, Gilbert S, Lodde M, Fradet Y, Toren P

Does 5-alpha Reductase Inhibitor Use Improve The Efficacy of Intravesical Bacille Calmette-Guerin (BCG) for Non-muscle Invasive Bladder Cancer?

Journal Article

Bladder Cancer, 6 (1), 2020.

| Links:

Vittrant B, Leclercq M, Martin-Magniette ML, Collins C, Bergeron A, Fradet Y, Droit A

Identification of a Transcriptomic Prognostic Signature by Machine Learning Using a Combination of Small Cohorts of Prostate Cancer

Journal Article

Front Genet, 11 , 2020.

Abstract | Links:

Vittrant B, Bergeron A, Molina OE, Leclercq M, Légaré XP, Hovington H, Picard V, Martin-Magniette ML, Livingstone J, Boutros PC, Collins C, Fradet Y, Droit A

Immune-focused multi-omics analysis of prostate cancer: leukocyte Ig-Like receptors are associated with disease progression

Journal Article

Oncoimmunology, 9 (1), 2020.

Abstract | Links:

Grosset AA, Dallaire F, Nguyen T, Birlea M, Wong J, Daoust F, Roy N, Kougioumoutzakis A, Azzi F, Aubertin K, Kadoury S, Latour M, Albadine R, Prendeville S, Boutros P, Fraser M, Bristow RG, van der Kwast T, Orain M, Brisson H, Benzerdjeb N, Hovington H, Bergeron A, Fradet Y, Têtu B, Saad F, Leblond F, Trudel D

Identification of intraductal carcinoma of the prostate on tissue specimens using Raman micro-spectroscopy: A diagnostic accuracy case-control study with multicohort validation

Journal Article

PLoS Med, 17 (8), 2020.

Abstract | Links:

Koti M, Berman DM, Siemens DR, Lange D, Wang E, Toren P, Eigl BJ, Hardy C, Purves R, Fradet V, Fradet Y, Mansure J, Kassouf W, Black PC,

Building a Canadian Translational Bladder Cancer Research Network

Journal Article

Can Urol Assoc J, 14 (10), 2020.

| Links:

Turcotte B, Paquet S, Blais AS, Blouin AC, Bolduc S, Bureau M, Caumartin Y, Cloutier J, Deschênes-Rompré MP, Dujardin T, Fradet Y, Lacombe L, Moore K, Morin F, Nadeau G, Simonyan D, Soucy F, Tiguert R, Toren P, Lodde M, Pouliot F

A prospective, multisite study analyzing the percentage of urological cases that can be completely managed by telemedicine

Journal Article

Can Urol Assoc J, 14 (10), 2020.

Abstract | Links:

Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, Ogawa O, Park SH, Lee JL, De Giorgi U, Bogemann M, Bamias A, Eigl BJ, Gurney H, Mukherjee SD, Fradet Y, Skoneczna I, Tsiatas M, Novikov A, Suarez C, Fay AP, Duran I, Necchi A, Wildsmith S, He P, Angra N, Gupta AK, Levin W, Bellmunt J,

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Journal Article

Lancet Oncol, 21 (12), 2020.

Abstract | Links:

353 entries « ‹ 4 of 36 › »
Signaler des ajouts ou des modifications

Active projects

  • Améliorer la réponse aux traitements en cancer de la vessie, from 2024-06-25 to 2026-10-01
  • Developement of a prostate cancer vaccine, from 2022-07-20 to 2025-05-01
  • En route vers de nouvelles avenues thérapeutiques en cancer de la prostate, from 2024-06-25 to 2026-10-01
  • Investigation multi-omiques des effets des acides gras oméga-3 et de la sélénonèine sur des organoïdes dérivés de patients atteints de cancer de la prostate., from 2024-07-02 to 2026-07-30
  • Repurposing bicalutamide to improve the response to immune checkpoint inhibition for treatment of advanced urothelial carcinoma, from 2022-08-01 to 2026-07-31
  • Targeting sex steroids to improve the response to bladder cancer immunotherapy, from 2021-10-01 to 2026-09-30
  • What are my options? A feasibility study of a personalized primary prevention strategy for women and men at high risk of breast and prostate cancer, from 2022-01-15 to 2025-03-31

Recently finished projects

  • CQDM_Projet de recherche PICT-01 sur le cancer de la prostate , from 2019-12-01 to 2022-11-30
  • En route towards prebiotic clinical trials for enhancement of immunotherapies in bladder and prostate cancers, from 2020-06-01 to 2024-04-30
  • Impact of lifestyle on gut barrier function, bacterial translocation and risk of prostate cancer, from 2020-09-01 to 2023-04-30
  • Maintien de colonies de souris transgéniques exprimant des molécules de CMH humaines , from 2022-03-22 to 2023-03-21
Data provided by the Université Laval research projects registery